FIE Stock Analysis: Fielmann Aktiengesellschaft | XETRA
Medical Instruments & Supplies | XETRA, Germany | Market Cap: 3.417m EUR | 12M Return: -27.6% | DE0005772206 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.09M
EPS Trend: 94.8%
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fielmann Group AG is a Germany-based vision care and audiology company that manufactures and sells optical products-including prescription glasses, frames, lenses, sunglasses, contact lenses, and ready-made reading aids-alongside hearing systems and personal protective equipment. It operates a multi-brand portfolio across multiple countries, serving customers through a combination of digital sales channels, brick-and-mortar retail stores, and an e-commerce platform (Befitting).
The company sits within the broader health care equipment and supplies industry, an area that benefits from long-term demographic tailwinds such as aging populations and rising incidence of vision and hearing impairment. Fielmanns vertically integrated business model-combining in-house manufacturing of eyewear with direct-to-consumer retail-helps it maintain competitive pricing and high store-level productivity, a key differentiator in the otherwise fragmented European optical retail market. The group is controlled by Korva SE and traces its origins to 1972 in Hamburg.
- US optical acquisitions accelerate international revenue growth
- German core market pressured by online optical competition
- Hearing aids segment expansion lifts group margin mix
| Net Income: 207.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -0.61 > 1.0 |
| NWC/Revenue: 4.44% < 20% (prev -12.93%; Δ 17.37% < -1%) |
| CFO/TA 0.17 > 3% & CFO 464.7m > Net Income 207.5m |
| Net Debt (1.26b) to EBITDA (532.0m): 2.37 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.4m) vs 12m ago 0.69% < -2% |
| Gross Margin: 27.23% > 18% (prev 80.23%; Δ -52.99% > 0.5%) |
| Asset Turnover: 97.56% > 50% (prev 98.27%; Δ -0.71% > 0%) |
| Interest Coverage Ratio: 7.56 > 6 (EBIT TTM 333.8m / Interest Expense TTM 44.1m) |
| A: 0.04 (Total Current Assets 676.4m - Total Current Liabilities 567.4m) / Total Assets 2.66b |
| B: 0.30 (Retained Earnings 807.5m / Total Assets 2.66b) |
| C: 0.13 (EBIT TTM 333.8m / Avg Total Assets 2.52b) |
| D: 0.60 (Book Value of Equity 998.2m / Total Liabilities 1.67b) |
| Altman-Z'' = 2.78 = A |
As of August 26, 2026, the stock is trading at EUR 39.40 with a total of 104,114 shares traded. Over the past week, the price has changed by -2.60%, over one month by +0.00%, over three months by -7.38% and over the past year by -27.62%.
Current recommended Stop Loss: 38.20 (which is 3% or 1.2 ATR below the current price).
Fielmann Aktiengesellschaft has no consensus analysts rating.
P/E Trailing = 16.6803
P/E Forward = 19.7628
P/S = 1.3985
P/B = 3.4805
P/EG = 3.2037
Revenue TTM = 2.46b EUR
EBIT TTM = 333.8m EUR
EBITDA TTM = 532.0m EUR
Long Term Debt = 278.8m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 98.2m EUR (from shortTermDebt, last fiscal year)
Debt = 1.48b EUR (from shortLongTermDebtTotal, last fiscal year) + Leases 599.9m
Net Debt = 1.26b EUR (calculated: Debt 1.48b - CCE 222.5m)
Enterprise Value = 4.68b EUR (3.42b + Debt 1.48b - CCE 222.5m)
Interest Coverage Ratio = 7.56 (Ebit TTM 333.8m / Interest Expense TTM 44.1m)
EV/FCF = 13.29x (Enterprise Value 4.68b / FCF TTM 352.0m)
FCF Yield = 7.52% (FCF TTM 352.0m / Enterprise Value 4.68b)
FCF Margin = 14.34% (FCF TTM 352.0m / Revenue TTM 2.46b)
Net Margin = 8.45% (Net Income TTM 207.5m / Revenue TTM 2.46b)
Gross Margin = 27.23% ((Revenue TTM 2.46b - Cost of Revenue TTM 1.79b) / Revenue TTM)
Gross Margin QoQ = 81.13% (prev -135.7%)
Tobins Q-Ratio = 1.76 (Enterprise Value 4.68b / Total Assets 2.66b)
Interest Expense / Debt = 2.98% (Interest Expense 44.1m / Debt 1.48b)
Taxrate = 29.16% (86.1m / 295.2m)
NOPAT = 236.4m (EBIT 333.8m * (1 - 29.16%))
Current Ratio = 1.19 (Total Current Assets 676.4m / Total Current Liabilities 567.4m)
Debt / Equity = 1.49 (Debt 1.48b / totalStockholderEquity, last quarter 998.2m)
Debt / EBITDA = 2.37 (Net Debt 1.26b / EBITDA 532.0m)
Debt / FCF = 3.58 (Net Debt 1.26b / FCF TTM 352.0m)
Total Stockholder Equity = 977.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.24% (Net Income 207.5m / Total Assets 2.66b)
RoE = 21.23% (Net Income TTM 207.5m / Total Stockholder Equity 977.4m)
RoCE = 26.57% (EBIT 333.8m / Capital Employed (Equity 977.4m + L.T.Debt 278.8m))
RoIC = 11.40% (NOPAT 236.4m / Invested Capital 2.07b)
WACC = 4.69% (E(3.42b)/V(4.90b) * Re(5.81%) + D(1.48b)/V(4.90b) * Rd(2.98%) * (1-Tc(0.29)))
Discount Rate = 5.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -32.42 | Cagr: 0.05%
[DCF] Terminal Value 76.38% ; FCFF base≈342.2m ; Y1≈365.0m ; Y5≈436.3m
[DCF] Fair Price = 64.80 (EV 6.70b - Net Debt 1.26b = Equity 5.44b / Shares 84.0m; r=8.35% [WACC [floored]]; 5y FCF grow 7.52% → 2.50% )
EPS Correlation: 94.83 | EPS CAGR: 54.49% | SUE: N/A | # QB: 0
Revenue Correlation: 98.50 | Revenue CAGR: 11.34% | SUE: -0.15 | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2025-12-31): EPS=2.39 | Chg30d=-0.28% | Revisions=+0% | GrowthEPS=+20.3% | GrowthRev=+8.0%
EPS next Year (2026-12-31): EPS=2.60 | Chg30d=-1.31% | Revisions=-57% | GrowthEPS=+0.1% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)